Expression of AID, P53, and Mlh1 proteins in endoscopically resected differentiated-type early gastric cancer

Yohei Takeda, Kazuo Yashima, Akihiro Hayashi, Shuji Sasaki, Koichiro Kawaguchi, Kenichi Harada, Yoshikazu Murawaki, Hisao Ito

Yohei Takeda, Kazuo Yashima, Akihiro Hayashi, Shuji Sasaki, Koichiro Kawaguchi, Kenichi Harada, Yoshikazu Murawaki, and Hisao Ito contributed equally to this paper.

Correspondence to: Dr. Kazuo Yashima, Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, 36-1 Nishicho, Yonago 683-8504, Japan. yashima@grape.med.tottori-u.ac.jp
Telephone: +81-859-386527 Fax: +81-859-386529
Received: January 19, 2012 Revised: March 14, 2012
Accepted: March 20, 2012
Published online: June 15, 2012

Abstract

AIM: To analyze the expression of the tumor-related proteins in differentiated-type early gastric carcinoma (DEGC) samples.

METHODS: Tumor specimens were obtained from 102 patients (75 males and 27 females) who had received an endoscopic tumor resection at Tottori University Hospital between 2007 and 2009. Ninety-one cancer samples corresponded to noninvasive or intramucosal carcinoma according to the Vienna classification system, and 11 samples were submucosal invasive carcinomas. All of the EGCs were histologically differentiated carcinomas. All patients were classified as having Helicobacter pylori (H. pylori) infections by endoscopic atrophic changes or by testing seropositive for H. pylori IgG. All of the samples were histopathologically classified as either tubular or papillary adenocarcinoma according to their structure. The immunohistochemical staining was performed in a blinded manner with respect to the clinical information. Two independent observers evaluated protein expression. All data were statistically analyzed then.

RESULTS: The rates of aberrant activation-induced cytidine deaminase (AID) expression and P53 overexpression were both 34.3% in DEGCs. The expression of Mlh1 was lost in 18.6% of DEGCs. Aberrant AID expression was not significantly associated with P53 overexpression in DEGCs. However, AID expression was associated with the severity of mononuclear cell activity in the non-cancerous mucosa adjacent to the tumor (P = 0.064). The rate of P53 expression was significantly greater in flat or depressed tumors than in elevated tumors. The frequency of Mlh1 loss was significantly increased in distal tumors, elevated gross-type tumors, papillary histological-type tumors, and tumors with a severe degree of endoscopic atrophic gastritis (P < 0.05).

CONCLUSION: Aberrant AID expression, P53 overexpression, and the loss of Mlh1 were all associated with clinicopathological features and gastric mucosal alterations in DEGCs. The aberrant expression of AID protein may partly contribute to the induction of nuclear P53 expression.

© 2012 Baishideng. All rights reserved.

Key words: Gastric cancer; Activation-induced cytidine deaminase; P53; Mlh1; Endoscopic resection

Peer reviewer: Jian-Kun Hu, MD, PhD. Associate Professor, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Takeda Y, Yashima K, Hayashi A, Sasaki S, Kawaguchi K, Harada K, Murawaki Y, Ito H. Expression of AID, P53, and Mlh1 proteins in endoscopically resected differentiated-type early gastric cancer. World J Gastrointest Oncol 2012; 4(6): 131-137
INTRODUCTION

Gastric cancer (GC) is the second leading cause of cancer death and the fourth most common malignant tumor in the world[3]. The mortality rate associated with the disease is high, with a 5-year survival rate of approximately 20% being observed worldwide[3]. The 5-year survival rate for GC is over 50% in Japan[4]. One of the main factors limiting the survival rate is late tumor detection. Therefore, a better understanding of the clinicopathological characteristics in early GC (EGC) is critical. Infection with Helicobacter pylori (H. pylori), especially when “cag” pathogenicity island (cag PAI) positive, increases the risk of developing GC by more than 6-fold. Therefore, cag PAI is considered an important carcinogenic trigger[4]. Almost all H. pylori strains in Japan are cag PAI-positive[4]. Infection with H. pylori causes chronic inflammation of the gastric mucosa, which slowly progresses through the premalignant stages of atrophic gastritis, intestinal metaplasia and adenoma/dysplasia to GC[4]. The Japanese Research Society for Gastric Cancer has proposed that GC is divided into differentiated and undifferentiated types according to the degree of glandular formation by the tumor cells[5]. Additionally, each type of cancer might follow different genetic pathways during carcinogenesis[6]. The frequency of differentiated-type carcinomas among total EGC is approximately 60%. Therefore, differentiated-type early gastric carcinoma (DEGC) is considered to represent the initial phase of GC[6].

Gastric carcinoma results from the accumulation of genetic and epigenetic alterations[4]. The frequency of MLH1 DNA methylation is 20%-30%[4,6] and the frequency of P53 gene mutations is 25%-50%[8,11] in sporadic GC. MLH1 is a DNA mismatch repair gene. Hypermethylation of the MLH1 promoter region is the main cause of microsatellite instability (MSI) in primary GCs[12]. Activation-induced cytidine deaminase (AID) is a DNA- and RNA-editing enzyme that was originally identified as an inducer of somatic hypermutation and class-switch recombination in the immunoglobulin genes[13]. Previous reports indicate that AID transgenic mice develop malignant T-cell lymphomas and lung adenomas. This finding suggests that aberrant AID expression results in tumor-related gene mutations and might be a cause of human malignancy[14]. It has been reported that cag PAI-positive H. pylori infection causes the aberrant expression of AID in the gastric epithelium. Aberrant AID expression leads to the accumulation of nucleotide alterations in the P53 gene[8]. Although the relationship between AID and Mlh1 is currently unclear, the expression of P53 has been reported to be inversely associated with Mlh1 loss in GC[8]. Elucidation of the relationship between the clinicopathological characteristics and the molecular events in EGC might improve the early detection, treatment, and surveillance of GC.

In this study, we evaluated AID, P53, and Mlh1 expression in endoscopically resected DEGCs and investigated their relationships with clinicopathological characteristics and background mucosa.

MATERIALS AND METHODS

Patient and tissue samples

Tumor specimens were obtained from 102 patients (75 males and 27 females) who had received an endoscopic tumor resection at Tottori University Hospital between 2007 and 2009 (Table 1). The mean age (± SD) was 70.6 ± 7.8 years (range: 55-92 years). The male patients were statistically younger than the female patients (69.4 ± 7.9 vs 74.2 ± 6.6, P = 0.006). We classified the DEGCs based on the Japanese classification of GC, 13th edition (7) according to location, macroscopic, and morphological types. The tumor location was defined as the upper third, middle third, or lower third of the tissue. The macroscopic type of DEGC was determined as elevated, depressed, or flat. All of the samples were histopathologically classified as either tubular or papillary adenocarcinoma according to their structure.

Ninety-one cancer samples corresponded to noninvasive or intramucosal carcinoma according to the Vienna classification system[16], and 11 samples were submucosal invasive carcinomas. All of the EGCs were histologically differentiated carcinomas. All patients were classified as having H. pylori infections by endoscopic atrophic changes or by testing seropositive for H. pylori IgG. Two experienced pathologists (Yashima K and Ito H) verified the pathological diagnoses. Moreover, we confirmed that these patients had no H. pylori eradication history. All specimens were assigned a new number without personal information to maintain anonymity. This study was approved by the institutional ethics committee of Tottori University (No. 314).

Evaluation of endoscopic gastric atrophy

All endoscopic examinations were performed using video scopes (model GIF-Q260; Olympus, Tokyo, Japan) and two endoscopists (Takeda Y and Yashima K) evaluated gastric atrophy according to the location of the atrophic border as described by Kimura et al[17]. A difference in the color and height of the gastric mucosa defines the border between the pyloric and fundic gland regions. We scored endoscopic gastric atrophy as marked (O2-O3), moderate (C3-O1) or mild (C1-C2). Previously, Takao et al[18] reported a significant correlation between endoscopic gastric atrophy (Kimura-Takemoto classification[17]) and the histological gastritis (updated Sydney system[19]). This suggests that the degree of endoscopic gastric atrophy can be considered as the grade of atrophic gastritis.

Evaluation of surrounding mucosal inflammation

We evaluated mononuclear cell activity in the non-can-
cerous mucosa adjacent to a tumor and scored it as mild, moderate or marked according to the updated Sydney system\(^{19}\).

**Immunohistochemical staining**

Paraffin-embedded sections (4 μm) were immunohistochemically stained with an anti-AID rat monoclonal antibody (EK2 5G9, Cell Signaling TECHNOLOGY, Danvers, CA, USA; dilution 1:400), an anti-P53 mouse monoclonal antibody (DO-7, Dakopatts, Copenhagen, Denmark; dilution 1:50), and an anti-Mlh1 mouse monoclonal antibody (G168-15, PharMingen, San Diego, CA, USA; dilution 1:50) using the avidin-biotin-peroxidase complex technique.

The immunohistochemical staining was performed in a blinded manner with respect to the clinical information. The sections were deparaffinized in xylene and rehydrated in ethanol. The sections were then immersed in a citrate buffer (0.01 mol/L, pH 6.0) and heated in a microwave oven for 20-30 min to retrieve antigens. The endogenous tissue peroxidase activity was blocked by incubation with 3% H\(_2\)O\(_2\). The sections were subsequently incubated with primary antibody overnight at 4 °C. As a negative control, the primary antibody was replaced with normal serum IgG at a similar dilution. The detection reaction followed the Vectastain Elite ABC kit protocol (Vector Laboratories, Burlingame, CA, USA) with diaminobenzidine as the chromogen. The sections were counterstained with hematoxylin. The sections were incubated with biotinylated anti-rat or anti-mouse IgG and avidin-biotin-peroxidase. The sections were subsequently visualized using diaminobenzidine tetrahydrochloride. Two independent observers (Takeda Y and Yashima K) evaluated protein expression.

**Assessment of AID immunostaining**

The internal positive controls were lymphocytes of germinal centers in lymphoid follicles (Figure 1A). The follicles contain activated B cells and intensely stained positive for AID in all specimens. The cytoplasm was scored as positive when > 30% of tumor cells were stained as strongly as the germinal centers.

**Assessment of P53 immunostaining**

The tumors were scored as positive for P53 when a distinct nuclear immunoreaction occurred in > 25% of tumor cells\(^{20}\) as shown in Figure 1B.

**Assessment of Mlh1 immunostaining**

The evaluation of Mlh1 expression was classified as either normal or decreased (Figure 1C). Tissue specimens with definite nuclear staining in < 30% of the tumor cells were categorized as having decreased staining\(^{21}\).

**Statistical analysis**

All data were statistically analyzed by the \(\chi^2\) test with Yates’ correction, Fisher’s test and the Mann-Whitney test (U-test) using Stat View 5.0 software (SAS Institute, Cary, NC, USA). Statistical significance was established at \(P<0.05\).

**RESULTS**

**Frequency of aberrant AID, P53, and Mlh1 expression**

Aberrant AID expression and P53 overexpression in DEGCs were detected in 35 (34.3%) cases. The loss of Mlh1 expression was observed in 19 (18.6%) cases. Among elderly patients (≥ 65 years old), the loss of Mlh1 expression in DEGCs was significantly higher in female patients than in male patients [10/26 (38.5%) vs 9/54 (16.7%), \(P = 0.004\)] (Table 2).

**Relationships between AID, P53 and Mlh1 expression**

The overexpression of P53 was significantly more frequent in patients with Mlh1-positive tumors than Mlh1-negative tumors [33/83(39.7%) vs 2/19(10.5%), \(P = 0.015\)] (Table 3). The overexpression of P53 was not associated with aberrant AID expression (\(P = 0.657\)).
The aberrant AID expression frequency was correlated with the location of DEGCs. However, there was no correlation between AID expression and tumor growth or histological type. The incidence of P53 overexpression in DEGCs was significantly more frequent in flat or depressed tumors than in elevated type tumors (28/64 (43.8%) vs 7/38 (18.4%), \( P = 0.009 \)) (Table 4). The overexpression of P53 was found more often in tubular tumors than in papillary adenocarcinoma (34/88 (38.6%) vs 1/14 (7.1%), \( P = 0.045 \)). A loss of Mlh1 expression was closely associated with distal location (\( P = 0.027 \)), elevated gross type (\( P = 0.039 \)) and papillary histological type (\( P = 0.033 \)).

**Relationship of AID, P53, and Mlh1 expression with tumor features**

The aberrant AID expression frequency was correlated with the location of DEGCs. However, there was no correlation between AID expression and tumor growth or histological type. The incidence of P53 overexpression in DEGCs was significantly more frequent in flat or depressed tumors than in elevated type tumors (28/64 (43.8%) vs 7/38 (18.4%), \( P = 0.009 \)) (Table 4). The overexpression of P53 was found more often in tubular tumors than in papillary adenocarcinoma (34/88 (38.6%) vs 1/14 (7.1%), \( P = 0.045 \)). A loss of Mlh1 expression was closely associated with distal location (\( P = 0.027 \)), elevated gross type (\( P = 0.039 \)) and papillary histological type (\( P = 0.033 \)).

**Relationships of AID, P53, and Mlh1 expression with background mucosa**

Although aberrant AID expression was not related to gastric atrophy, mononuclear cell activity tended to be marked in the surrounding mucosa adjacent to DEGCs with aberrant AID expression (\( P = 0.064 \)). The P53 expression in DEGCs was not associated with gastric atrophy and mononuclear cell activity in the surrounding mucosa. The loss of Mlh1 expression in DEGCs was associated with marked endoscopic gastric atrophy (\( P = 0.020 \)) and mild mononuclear cell activity (\( P = 0.053 \)) (Table 5).

**DISCUSSION**

The present study examined AID, P53 and Mlh1 expres-
sion in endoscopically resected DEGCs, and these results were compared with the clinicopathological characteristics and the surrounding mucosa. Aberrant AID expression in endoscopically resected DEGCs significantly correlated with marked mononuclear cell activity in tumor background mucosa but not with P53 overexpression. In addition, P53 expression significantly correlated with flat or depressed types of gross tumor appearance. The loss of Mlh1 expression correlated with elevated type, papillary type histology, distal location and severe endoscopic atrophic gastritis.

Infection with *H. pylori* triggers aberrant AID expression in the gastric epithelium, which leads to the accumulation of altered nucleotides in the *P53* gene. The rate of aberrant AID expression in DEGC (34.3%) was slightly higher than the 26.9% and 22.5% described in two previous reports. The variability in the findings may be caused by differences in the stage of carcinoma progression and the degree of tumor differentiation. All of our data were obtained from endoscopically resected, well-differentiated early carcinomas.

Previously, Kim et al. found a significant association between aberrant AID expression and the nuclear overexpression of P53 in various types of GCs. However, we did not find a relationship between aberrant AID expression and P53 overexpression in DEGCs. Similarly, Goto et al. found no correlation between AID and P53 in early differentiated and poorly differentiated GCs. There are several possible explanations for these different findings. One explanation is that nonsense mutations were considered to be false-negative. Additionally, P53 protein could accumulate to repair damaged DNA in false-positive cells without P53 mutations. The rate of P53 expression might also increase with tumor progression. Moreover, P53 protein might become altered through cigarette smoking, as in lung and esophageal carcinogenesis. Further investigation is needed to clarify the correlation between the expression of P53 and aberrant AID expression.

The expression of AID in gastric epithelial cells could be altered by the direct action of *H. pylori* macromolecules through the type IV secretion system encoded by cag PAI. Additionally, *H. pylori* infection is associated with inflammatory cytokines, such as tumor necrosis factor α, that are produced during gastric inflammation. Furthermore, AID expression in tumors such as hepatocellular carcinoma, cholangiocarcinoma and colon cancer is also mediated by proinflammatory cytokine stimulation. Aberrant AID expression correlates with chronic active inflammation, glandular atrophy and intestinal metaplasia in the non-neoplastic gastric mucosa. The present study found that aberrant AID expression in tumors correlated with mononuclear cell activity in the mucosa surrounding the tumor, which would support the mechanisms of AID expression.

The 33.7% frequency of P53 overexpression in the

---

### Table 4 Relationships of activation-induced cytidine deaminase, P53 and Mlh1 expression with tumor features

| Tumor location | AID | P53 | Mlh1 |
|---------------|-----|-----|------|
| Upper third   | 4   | 19  | 0.067 | 8   | 15 | 0.543 | 22 | 1 | 0.027 |
| Middle third  | 13  | 27  | 0.202 | 16 | 24 | 0.009 | 34 | 6 |
| Lower third   | 18  | 21  | 0.673 | 11 | 28 | 0.045 | 27 | 12 |
| Tumor growth  | 19  | 45  | 0.540 | 9  | 16 | 0.376 | 20 | 5 | 0.020 |
| Flat/depressed|     |     |       |    |    |       |    |    |       |
| Elevated      | 16  | 22  | 0.064 | 7  | 22 | 0.232 | 14 | 8 | 0.053 |
| Histological type | | | | | | | | | |
| Tubular       | 29  | 59  | 0.543 | 34 | 54 | 0.045 | 75 | 13 |
| Papillary     | 6   | 8   | 0.009 | 1  | 13 | 0.020 | 8  | 6 |

AID: Activation-induced cytidine deaminase.

### Table 5 Relationships of activation-induced cytidine deaminase, P53 and Mlh1 expression with background mucosa

| Endoscopic gastric atrophy | AID | P53 | Mlh1 |
|----------------------------|-----|-----|------|
| Mild                       | 8   | 17  | 0.540 | 9  | 16 | 0.376 | 20 | 5 | 0.020 |
| Moderate                   | 19  | 29  | 0.064 | 19 | 29 | 0.232 | 44 | 4 |
| Marked                     | 8   | 21  | 0.009 | 7  | 22 | 0.045 | 19 | 10 |
| Mononuclear cell activity  |     |     |       |    |    |       |    |    |       |
| Mild                       | 5   | 17  | 0.543 | 4  | 17 | 0.232 | 14 | 8 | 0.053 |
| Moderate                   | 24  | 47  | 0.064 | 28 | 44 | 0.009 | 61 | 10 |
| Marked                     | 6   | 3   | 0.045 | 3  | 6  | 0.020 | 8  | 1 |

AID: Activation-induced cytidine deaminase.
DEGC was consistent with previous findings\textsuperscript{[8]}. The expression of P53 was associated with flat or depressed macroscopic tumor features but not with the other clinicopathological features of age, gender, or location and tumor size. In agreement with our results, Sasaki \textit{et al.}\textsuperscript{[9]} also demonstrated that P53 overexpression is more frequent in depressed-type differentiated GCs.

Several epigenetic alterations in GC have been described\textsuperscript{[10,16]}. DNA methylation of \textit{MLH1} promoter region CpG islands is closely associated with a loss of \textit{Mlh1} expression in GCs that exhibit MSI\textsuperscript{[10]}. \textit{MLH1} hypermethylation is evident in 20%-28% of differentiated carcinomas\textsuperscript{[10,34]}. The reported frequency of negative \textit{Mlh1} expression in both early and sporadic GC ranges from 13%-20%\textsuperscript{[16,34,35]}. In the present study, the frequency of lost \textit{Mlh1} expression in DEGCs was 18.6%. Our study and previous studies have shown that GCs with reduced \textit{Mlh1} expression are statistically more prevalent among elderly women. Previous reports have suggested that high-frequency MSI (MSI-H) GCs are characterized by an antral location and proliferation. A loss of \textit{Mlh1} expression was associated with the lower third of the stomach and elevated gross type in our study. Additionally, our findings were consistent with the Guos report\textsuperscript{[7]}, which showed a higher prevalence of MSI-H in papillary type GC than in early well-differentiated carcinoma.

Chronic gastritis induced by \textit{H. pylori} infection usually progresses to atrophic gastritis, which is an established risk factor for GC. The risk increases with the degree and the extent of atrophic gastritis. However, no clinicopathological studies regarding the relationship between molecular events and the degree of endoscopic atrophy in patients with GC have been published. Factors such as aging, dietary habits, alcohol consumption, cigarette smoking and autoimmunity promote atrophic gastritis\textsuperscript{[18,30]}. The frequency of \textit{Mlh1} loss increases in tumors that cause a severe degree of endoscopic atrophic gastritis. Our results suggest that several factors are involved in the gastric atrophic changes found in patients with DEGC accompanied by aberrant \textit{Mlh1} expression. However, more studies are required to identify the mechanism of this association. Moreover, significantly less mononuclear cell infiltration was evident in patients with DEGC that had lost \textit{Mlh1}. These results might be a consequence of a reduction in \textit{H. pylori} density accompanied with severe glandular atrophy, which might contribute to reduced inflammatory infiltration.

In conclusion, we investigated the relationships between AID, P53 and \textit{Mlh1} expression, clinicopathological characteristics, and mucosal alterations. Our results suggest that aberrant AID expression may partly contribute to P53 overexpression.
Takeda Y et al. Early gastric cancer and tumor-related protein expression

11 Yamazaki K, Tajima Y, Makino R, Nishino N, Aoki S, Kato M, Sakamoto M, Morohara K, Kaetsu T, Kusano M. Tumor differentiation phenotype in gastric differentiated-type tumors and its relation to tumor invasion and genetic alterations. J World J Gastroenterol 2006; 12: 3803-3809

12 Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090-1095

13 Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 533-563

14 Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T. Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003; 197: 1173-1181

15 Matsumoto Y, Murasawa H, Kinoshita K, Endo Y, Koutou H, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007; 13: 470-476

16 Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwashita M, Iwashita A, Kim YL, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255

17 Kimura T, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87-97

18 Takao T, Ishikawa T, Ando T, Takao M, Matsumoto T, Itozaki Y, Okita M, Nagao Y, Oyamada H, Yokoyama K, Tatebe A, Uchiyama T, Handa O, Takagi T, Yagi N, Kobayashi H, Yonezawa M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastric cancer. Arch Pathol Lab Med 2011; 135: 889-898, 898.e1-898.e3

19 Andachi H, Yashima K, Koda M, Kawaguchi K, Kitamura A, Hosoda A, Kishimoto Y, Shiota G, Ito H, Makino M, Kaibara T, Nakasone H, Morisawa T, Murawaki Y. Reduced Fhit expression is associated with mismatch repair deficiency in human adenomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 2000; 31: 1033-1035

20 Ohmura K, Tamura G, Endoh Y, Sakata K, Takahashi T, Motoyama T. Microsatellite alterations in differentiated-type human gastric adenocarcinoma and hMLH1 promoter in gastric cancers. Br J Cancer 2001; 85: 1147-1152

21 Baek MJ, Kang H, Kim SE, Park JH, Lee JS, Paik YK, Kim H. Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability. Br J Cancer 2001; 85: 877-880

22 Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, Chiba T. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer 2008; 123: 2735-2740

23 Kim CJ, Song JH, Cho YG, Cao Z, Kim SY, Nam SW, Lee JY, Park WS. Activation-induced cytidine deaminase expression in gastric cancer. Tumour Biol 2007; 28: 333-339

24 Goto A, Hirahashi M, Osada M, Nakamura K, Yao T, Tsucheyoshi M, Takayanagi R, Oda Y. aberrant activation-induced cytidine deaminase expression is associated with mucosal intestinalization in the early stage of gastric cancer. Virchows Arch 2011; 458: 717-724

25 Ashcroft M, Kubbatt MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19: 1751-1758

26 Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994; 18: 1247-1253

27 Pfeifer GP, Denissenko MF, Olivier M, Tretyakov SS, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435-7451

28 Saeki H, Ohno S, Miyazaki M, Araki K, Egashira A, Kawaguchi H, Watanabe M, Morita M, Sugimachi K. p53 protein accumulation in multiple oesophageal squamous cell carcinomas: relationship to risk factors. Oncology 2002; 62: 175-179

29 Viala J, Chaput C, Boneca IG, Cordona A, Girardin SE, Moran AP, Athman R, Mønæt S, Huerre MR, Coyle AJ, Di Stefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-1174

30 Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, Kinoshita K, Honjo T, Chiba T. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008; 135: 889-898, 898.e1-898.e3

31 Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watahki K, Shimotohno K, Honjo T, Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 2007; 26: 5587-5595

32 Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008; 47: 888-896

33 Ohmura K, Tamura G, Endoh Y, Sakata K, Takahashi T, Motoyama T. Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 2000; 31: 1033-1035

34 Kim HG, Lee S, Kim DY, Ryu SY, Joo JK, Kim JC, Lee KH, Lee JH. Aberrant methylation of DNA mismatch repair genes in elderly patients with sporadic gastric carcinoma: A comparison with younger patients. J Surg Oncol 2010; 101: 28-35

35 Nakajima T, Akiyama Y, Shiraishi J, Arai T, Yanagisawa Y, Arai M, Fukuda Y, Sawabe M, Saitoh K, Kamiyama R, Hirokawa K, Yuasa Y. Age-related hypermethylation of the hMLH1 promoter in gastric cancers. Int J Cancer 2001; 94: 208-211

36 Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, Cecarelli K, Sera F, Mariani-Costantini R, Nesi G, Palli D, Ottini L. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925-932

37 Guo RJ, Arai H, Kitayama Y, Igarashi H, Hemmi H, Arai T, Hanai H, Sugimura H. Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa. Pathol Int 2001; 51: 240-247

38 Nakamura M, Haruma K, Kamada T, Mihara M, Yoshiihara M, Sumioka M, Fukuhara T, Chayama K. Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects. Dig Dis Sci 2002; 47: 675-681

39 Dai YC, Tang ZP, Zhang YL. How to assess the severity of atrophic gastritis. World J Gastroenterol 2011; 17: 1690-1693

S- Editor Wang JL  L- Editor Hughes D  E- Editor Zheng XM